Status: Not yet recruiting
Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML
The purpose of this study is to evaluate the safety and tolerability of mezigdomide in combination with ziftomenib in adolescent and adult participants with either KMT2A-rearranged (KMT2A-r) or NPM1-mutant relapsed or refractory acute myeloid leukemia (AML).
Participants needed: 24
Trial details
Phase: Phase 1Age: 12+Biological sex: AllType: InterventionalSponsor: Massachusetts General HospitalUpdated: Jan 22, 2026Locations: 2
Eligibility criteria
Age ≥16 years during dose escalation portion of study, patients must weigh ≥40 k... [+13]
AML diagnosis without KMT2A-rearrangement or NPM1-mutation. KMT2A-PTD patients a... [+18]